Rutgers scientists form immuno-oncology biotech to develop pipeline of TAM inhibitors
There are thousands of immuno-oncology therapies in the global pipeline, and researchers from Rutgers are adding to that tally, with a family of compounds …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
